
Photo taken from newatlas.com
Jul 25, 2024, 02:35
Guru P. Sonpavde: Pleased to review emerging vaccine immunotherapy approaches to treat bladder cancer
Guru P. Sonpavde, GU Oncology Director at Advent Health Cancer Institute, shared on X:
“Pleased to review emerging vaccine immunotherapy approaches to treat bladder cancer, urothelial carcinoma.
We discuss:
1) peptide,
2) cellular and
3) nucleic acid (DNA, RNA) approaches
Several challenges remain:
1) heterogeneity of cancer cells,
2) Immunogenicity of antigens/neoantigens,
3) downregulation of antigen presentation,
4) Inhibitory immune microenvironment,
5) cost and efficiency of manufacturing processes to have a global impact”
Vaccine approaches to treat urothelial cancer
Autors: Giulia Claire Giudice and Guru P. Sonpavde.
Source: Guru P. Sonpavde/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 21, 2025, 13:29
Feb 21, 2025, 13:07
Feb 21, 2025, 13:06
Feb 21, 2025, 13:03
Feb 21, 2025, 13:00
Feb 21, 2025, 12:53
Feb 21, 2025, 12:41
Feb 21, 2025, 12:39